Treatment process of cyclosporine eye gel

A treatment process, the technology of cyclosporine, applied in the field of medicine, can solve the problems of no commercial production value and feasibility, easy clogging of filter membranes, difficulty in ensuring production efficiency, etc., achieve good industrial application prospects, reduce product impurities, The effect of improving productivity

Inactive Publication Date: 2018-05-25
ZHAOKE GUANGZHOU OPTHALMIC DRUG
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The first type is difficult to purchase qualified sterile raw and auxiliary materials, and the preparation process and workshop environment are all aseptic, the production cost is high and difficult; It is also better, but cyclosporine itself is not resistant to high temperature, which leads to more degradation impurities of cyclosporine, increases the safety risk of preparations, and produces side effects; the third terminal sterilization process for final products can only be used for small-scale process, It is difficult to produce commercially, because the viscosity of the emulsion gel is high, it is easy to block the filter membrane with small pore size, and the filtration is very slow, so the production efficiency is difficult to guarantee
[0005] Patent No. CN201410033737.3 "A Cyclosporine Eye Gel and Its Preparation Method", which disclosed the use of moist heat sterilization to ensure sterility, reproducible detection found that damp heat sterilization caused cyclosporine to produce degradation impurities
[0006] The patent No. CN201510785005.4 is "A Cyclosporine Ophthalmic Emulsion Composition", which uses sterile raw materials and excipients to prepare preparations. This process is very difficult to apply in industry
The patent number is CN201610172271.4 "Cyclosporin Ophthalmic Emulsion", which adopts the terminal sterilization and filtration of the prepared emulsion. For viscous emulsion, it is difficult to pass through a 0.22 micron sterile filter, so it does not have Operability
In summary, the various aseptic processes currently disclosed do not have the value and feasibility of commercial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment process of cyclosporine eye gel
  • Treatment process of cyclosporine eye gel

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Cyclosporin A eye gel process

[0032] 1. Preparation of Carbomer 981 matrix:

[0033] (1) Add an appropriate amount of water for injection into the liquid preparation tank, add the prescribed amount of Carbomer 981, stir and homogenize;

[0034] (2) Add an appropriate amount of water for injection into the liquid distribution tank, stir and homogenize;

[0035] (3) The matrix swells at rest, and the swelling time is 12 hours;

[0036] (4) Open the equipment, stir and homogenize;

[0037] (5) 115°C, sterilize the matrix with damp heat for 80 minutes, stir and circulate at the same time, cool the matrix to below 40°C, and vacuumize to remove air bubbles;

[0038] 2. Adjustment of pH: Use sodium hydroxide solution to adjust the pH of the matrix to 6.0, and continue to stir for an appropriate time;

[0039] 3. Cyclosporin A main drug solution and sterilizing filter are added to the liquid preparation tank:

[0040] (1) Take the castor oil polyoxyl ester (35) of the pr...

Embodiment 2

[0048] Cyclosporin A eye gel process

[0049] 1. Preparation of Carbomer 981 matrix:

[0050] (1) Add an appropriate amount of water for injection into the liquid preparation tank, add the prescribed amount of Carbomer 981, stir and homogenize;

[0051] (2) Add an appropriate amount of water for injection into the liquid distribution tank, stir and homogenize;

[0052] (3) The matrix swells at rest, and the swelling time is 19 hours;

[0053] (4) Open the equipment, stir and homogenize;

[0054] (5) 117°C, sterilize the matrix with moist heat for 31 minutes, stir and circulate at the same time, cool the matrix to below 40°C, and vacuumize to remove air bubbles;

[0055] 2. Adjustment of pH: Use sodium hydroxide solution to adjust the pH of the matrix to 7.0, and continue to stir for several minutes;

[0056] 3. Cyclosporin A main drug solution and sterilizing filter are added to the liquid preparation tank:

[0057] (1) Take the castor oil polyoxyl ester (35) of the presc...

Embodiment 3

[0065] Cyclosporin A eye gel process

[0066] 1. Preparation of Carbomer 981 matrix:

[0067] (1) Add an appropriate amount of water for injection into the liquid preparation tank, add the prescribed amount of Carbomer 981, stir and homogenize;

[0068] (2) Add an appropriate amount of water for injection into the liquid distribution tank, stir and homogenize;

[0069] (3) The matrix is ​​left to swell, and the swelling time is 24 hours;

[0070] (4) Open the equipment, stir and homogenize;

[0071] (5) 121°C, sterilize the matrix with damp heat for 20 minutes, stir and circulate at the same time, cool the matrix to a temperature below 40°C, and vacuumize to remove air bubbles;

[0072] 2. Adjustment of pH: Use sodium hydroxide solution to adjust the pH of the matrix to 9.0, and continue to stir for several minutes;

[0073] 3. Cyclosporin A main drug solution and sterilizing filter are added to the liquid preparation tank:

[0074] (1) Take the castor oil polyoxyl ester ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines, and discloses a treatment process of cyclosporine eye gel. The treatment process comprises the following steps: adding water into carbomer for full stirring and homogenization, swelling a prepared carbomer matrix, and performing stirring and homogenization; performing moist heat sterilization on the matrix, then cooling the matrix, and performing vacuumizing debubbling treatment; adjusting the pH of the matrix to 5.0 to 9.0 through a filtered sodium hydroxide solution; fully mixing castor oil polyoxyhydrocarbon ester (35), ciclosporin A raw material, 1,2-propylene glycol and water to prepare a clarified solution under a water bath condition at 35 to 45 DEG C; filtering the clarified solution, uniformly mixing filtrate with the matrix, and performing vacuumizing debubbling; performing filtration again and sterile filling. According to the process disclosed by the invention, before the carbomer is added, sterilization and filtration are performed, so that industrial production is facilitated; only partial germfree treatment is required; purchasing is facilitated, and the cost can be reduced; furthermore, thermal degradation of ciclosporin is avoided, and product impurities are reduced; all indexes are qualified through detection; the treatment process has a good industrial application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a treatment process for cyclosporine eye gel. Background technique [0002] Cyclosporin A is a cyclic polypeptide containing 11 amino acids extracted from fungi, and is a third-generation highly effective immunosuppressant that can be used to treat dry eye disease. [0003] For ophthalmic preparations, the state requires that they be managed as injections, so the sterility of the preparations is very important. At present, there are three main aspects of sterility assurance: sterilization and filtration process, aseptic process and terminal sterilization process. Cyclosporin is poorly soluble and thermally unstable, so the sterile preparation of cyclosporine is a difficult problem. [0004] At present, the following three methods are mainly used for aseptic treatment: purchasing aseptic raw materials and operating in a sterile environment; moist heat sterilization of the final product; ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/13A61K9/06A61K47/32A61K47/44A61K47/10A61P27/02
CPCA61K9/0048A61K9/06A61K38/13A61K47/10A61K47/32A61K47/44A61K9/107A61P27/02
Inventor 李刚曹开磊李小羿戴向荣殷雷凌娟
Owner ZHAOKE GUANGZHOU OPTHALMIC DRUG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products